Compare CHRS & FNLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHRS | FNLC |
|---|---|---|
| Founded | 2010 | 1864 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.8M | 306.9M |
| IPO Year | 2014 | 1995 |
| Metric | CHRS | FNLC |
|---|---|---|
| Price | $1.66 | $28.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 9.5K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 5.19% |
| EPS Growth | ★ 472.00 | 26.34 |
| EPS | N/A | ★ 0.80 |
| Revenue | N/A | N/A |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | N/A |
| P/E Ratio | ★ N/A | $35.39 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $23.36 |
| 52 Week High | $2.62 | $30.33 |
| Indicator | CHRS | FNLC |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 45.73 |
| Support Level | $1.55 | $28.29 |
| Resistance Level | $1.80 | $28.55 |
| Average True Range (ATR) | 0.11 | 0.67 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 6.93 | 20.38 |
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.